Swiss drugmaker Novartis predicted that the Australian government would not defend its nuclear medicine world technology ...

The results from these pivotal trials have firmly positioned 177 Lu-PSMA-617 therapy within the standard therapeutic arsenal for mCRPC. However, questions remain regarding identifying which patients ...

In a recent MedPage Today video, Neeraj Agarwal, MD, of the Huntsman Cancer Institute at the University of Utah in Salt Lake ...

Scientists from Tomsk Polytechnic University, in collaboration with their colleagues, supported by the federal Priority-2030 ...

and lutetium 177 vipivotide tetraxetan (177 Lu-PSMA-617) for patients with prostate-specific membrane antigen (PSMA) PET-avid disease. While these targeted therapies have improved outcomes, there is ...

When we last looked at Lantheus in May, its stock was trading just under $80 a share. As a reminder, Lantheus Holdings, Inc.

“Prostate-specific membrane antigen (PSMA) PET imaging can identify patients suitable for PSMA-targeted radioligand therapy such as lutetium-177-PSMA-617. This is crucial for mCRPC patients who have ...

The PSMA-PET imaging agent will be used for patients who have suspected metastasis and those with suspected cancer recurrence.

The first patient has been dosed in a phase 1b/2a trial (NCT06785636) of pocenbrodib, a CBP/p300 inhibitor, as a monotherapy and in combination with abiraterone acetate (Zytiga), olaparib (Lynparza), ...